Expressions of c-IAP2 and Smac gene in leukemia and their clinical significance.
- Author:
Yan WANG
1
;
Jian-Hui ZHOU
Author Information
1. Department of Hematology, The Second Hospital, Hebei Medical University, Shijiazhuang 050000, China.
- Publication Type:Journal Article
- MeSH:
Acute Disease;
Biomarkers, Tumor;
Humans;
Inhibitor of Apoptosis Proteins;
biosynthesis;
genetics;
Intracellular Signaling Peptides and Proteins;
genetics;
Leukemia;
metabolism;
Mitochondrial Proteins;
biosynthesis;
genetics;
Prognosis;
RNA, Messenger;
biosynthesis;
genetics;
Reverse Transcriptase Polymerase Chain Reaction
- From:
Journal of Experimental Hematology
2006;14(2):217-220
- CountryChina
- Language:Chinese
-
Abstract:
To investigate the expressions of c-IAP2 and Smac in leukemia and their prognostic significance in adult patients with acute leukemia (AL), the mRNA expressions of c-IAP2 and Smac in 103 AL adult patients were measured by semi-quantity reverse transcription polymers chain reaction (RT-PCR). Other 20 adults were selected as normal controls (NC), K562 and Kg-1alpha cell lines were employed as positive control. The results showed that the expressions of c-IAP2 and Smac in de novo AL patients were higher than those in NC, while they decreased in patients at complete remission (CR). In relapsed patients, the expressions of c-IAP2 and Smac increased again. The mRNA expression of c-IAP2 and Smac in CML-CP were higher than that of NC, but no statistical significance was found (P > 0.05). In AL patients, the CR rate of c-IAP2+ and Smac+ cases were lower than those of c-IAP2- and Smac- cases. It is concluded that overexpression of c-IAP1 and Smac may play a synergic role in the pathogenesis of AL, and there is a positive correlation beween them. The c-IAP2 and Smac expressions are associated with remission rate in AL, while the patients with high level of c-IAP2 or Smac have low remission rates. It seems that c-IAP2 and Smac serve as markers of poor prognosis in AL.
